SRX Global Inc. entered into a Stock Purchase Agreement to acquire all outstanding capital stock of CERo Therapeutics, Inc., the wholly owned subsidiary of CERo Therapeutics Holdings, Inc. At closing, SRX will issue shares valued at $1 million based on the lower of the prior day's closing price or 20-day VWAP, forgive up to $11.7 million in principal under a Consolidated Senior Secured Promissory Note, and assume approximately $1.6 million in liabilities. The transaction includes a 30-day go-shop period allowing Holdings to solicit superior proposals, with reciprocal $750,000 termination fees. Closing is conditioned on the acquisition of Holdings' preferred stock and necessary consents. SRX Global Inc. operates in the healthcare sector.
